INTRODUCTION {#rjy362s1}
============

Ewing's sarcoma is a rare and aggressive tumor which classified as peripheral primitive neuroectodermal tumor \[[@rjy362C1]\]. It was first described by James Ewing, an American pathologist, in 1921 \[[@rjy362C2]\]. Ewing's sarcoma commonly occurs in early childhood and adolescence, but rarely in adulthood \[[@rjy362C3]\]. Most cases arise in the long bones of the extremities \[[@rjy362C1], [@rjy362C2], [@rjy362C4]\]. Primary Ewing's sarcoma of the head and neck is uncommon, hence it accounts for only 1--4% of all Ewing's sarcomas \[[@rjy362C1], [@rjy362C4], [@rjy362C5]\]. Furthermore, sinonasal tract involvement is very rare and only few reported cases have been published in world literature \[[@rjy362C2], [@rjy362C4]\].

CASE REPORT {#rjy362s2}
===========

A 24-year-old male patient who presented with a history of right nasal obstruction, right eye pain, lower eyelid swelling and orbital swelling. Endoscopic examination revealed an obstructive mass occupying the right nasal cavity (Fig. [1](#rjy362F1){ref-type="fig"}). Cranial nerves were intact. The result of hematological and biochemical investigations were within normal limits.

![Nasal endoscopy image showing a soft tissue mass arising from the right lateral nasal wall.](rjy362f01){#rjy362F1}

On radiological evaluation, CT scan with contrast of the paranasal sinuses (PNS) revealed a mass involving the right ethmoid sinus with medial wall and orbital floor extension (Fig. [2](#rjy362F2){ref-type="fig"}). The subsequent magnetic resonance imaging (MRI) revealed an infiltrative soft tissue mass occupying the right ethmoid sinus, eroding inferio-medial orbital wall and extending to the extracoanal space (Fig. [3](#rjy362F3){ref-type="fig"}). Positron emission tomography (PET) scan demonstrated an ill-defined 4.5 × 4.2 cm^2^ mass lesion in the right nasal cavity and ethmoid sinus extending to the right medial orbital floor (Fig. [4](#rjy362F4){ref-type="fig"}). The scan did not reveal any associated lymphadenopathies.

![Contrast enhanced computed tomography scan. Coronal CT scan with contrast of PNS showing an enhancing soft tissue lesion in the right ethmoid, eroding the medial and inferior orbital walls.](rjy362f02){#rjy362F2}

![Magnetic resonance imaging (MRI) showing an enhancing soft tissue mass in the ethmoid sinus, eroding inferio-medial orbital wall.](rjy362f03){#rjy362F3}

![Positron emission tomography scan. PET scan showing an ill-defined 4.5 × 4.2 cm^2^ mass lesion in the right nasal cavity, maxillary and ethmoid sinuses extending to the right medial orbital floor.](rjy362f04){#rjy362F4}

Histological analysis of a biopsy from the mass revealed a small rounded blue cell tumor suggestive of Ewing's sarcoma/primitive neuroectodermal tumor. Immunohistochemistry showed the neoplastic cells are positive for CD99, S-100 protein and vimintin. However, neuron specific enolase (NSE), smooth muscle actin (SMA), desmin, myogenin, CD45, synaptophysin and pan-cytokeratin were all negative. KI-67 index was 30--40%.

Subsequently, molecular study using fluorescence in situ hybridization (FISH) had shown rearrangement of EWSR1 gene in 100% of the analyzes nuclei that confirm the diagnosis of Ewing's sarcoma. The patient underwent endoscopic excision of the tumor followed by chemotherapy and radiotherapy treatment. MRI 6-months post treatment showed complete resolution of the disease (Fig. [5](#rjy362F5){ref-type="fig"}). The patient remains symptom-free during 2 years follow-up and maintains a very good quality of life.

![Magnetic resonance imaging after treatment. MRI post treatment showing total resolution of the tumor.](rjy362f05){#rjy362F5}

DISCUSSION {#rjy362s3}
==========

Ewing's sarcoma is an aggressive tumor that commonly arises in the long bones or pelvis and less frequently in the soft tissue of the trunk and extremities \[[@rjy362C1], [@rjy362C2]\]. It is a rare disease comprising 4--6% of all primary bone tumors \[[@rjy362C1], [@rjy362C5], [@rjy362C6]\]. Ewing's sarcoma of the head and neck is uncommon, accounting for 1--4% of all cases \[[@rjy362C1], [@rjy362C4], [@rjy362C5]\]. Moreover, Ewing's sarcomas in the nasal cavity and PNS are extremely rare \[[@rjy362C1], [@rjy362C5]\]. Pediatrics and adolescents are more susceptible to the disease \[[@rjy362C3]\]. About 80% of patients are younger than 20 years of age with the highest incidence in the second decade of life \[[@rjy362C2], [@rjy362C3], [@rjy362C6]\]. Ewing's sarcoma is more common in white populations, and have a slight male predominance \[[@rjy362C4], [@rjy362C5]\].

Clinically, majority of the patients are presented with enlarging mass, nasal obstruction, rhinorrhea and epistaxis \[[@rjy362C4], [@rjy362C7]\]. Other symptoms and signs are due to mass effect of the tumor \[[@rjy362C4], [@rjy362C7]\]. In particular, patients with periorbital extension may present with proptosis, periorbital edema and decrease visual acuity \[[@rjy362C7]\]. Approximately 15--30% of the patients are presented with metastasis at time of diagnosis \[[@rjy362C7]\]. The most common sites of distant metastasis are the lungs and bones \[[@rjy362C7]\]. Microscopically, Ewing's sarcomas are composed of uniform small round cells with round nuclei containing fine chromatin, scanty clear or eosinophilic cytoplasm and PAS‑positive intracytoplasmic glycogen granules \[[@rjy362C2], [@rjy362C7], [@rjy362C8]\].

Diagnosing sinonasal Ewing's sarcoma is extremely challenging as several small round neoplasms must be excluded \[[@rjy362C1], [@rjy362C2], [@rjy362C9]\]. The differential diagnosis is widely broad including rhabdomyosarcoma, lymphoma, undifferentiated carcinoma, melanoma and olfactory neuroblastoma \[[@rjy362C2], [@rjy362C6]\]. The diagnosis of Ewing's sarcoma can be established after a careful evaluation using radiological study, histopathological examination, immunohistochemistry, and cytogenetic analysis \[[@rjy362C2], [@rjy362C9]\]. The immunohistochemical profile usually shows CD99 and Fli-1 positivity \[[@rjy362C2], [@rjy362C8]\]. In 2011, Hafezi reviewed 14 cases of sinonasal Ewing's sarcoma \[[@rjy362C6]\]. All cases were positive for CD99 in the immunohistochemistry staining \[[@rjy362C6]\]. In the present case, immunohistochemistry revealed positive staining for CD99, S-100 protein and vimintin. A definitive diagnosis of Ewing's sarcoma can be achieved through molecular analysis that detect EWSR1/FLI-1 fusion \[[@rjy362C1]\]. This fusion causes a specific t(11:22)(q24:q12) chromosomal translocation \[[@rjy362C1]\].

The prognosis depends on the site of the primary tumor, the presence of distant metastasis at presentation, and the age of the patient \[[@rjy362C2], [@rjy362C3]\]. Researchers have found that patients younger than 15 years old and patients with axial and sinonasal tract diseases have a better prognosis \[[@rjy362C2], [@rjy362C3]\]. Furthermore, a good prognosis can be expected if the disease has not metastasized \[[@rjy362C2]--[@rjy362C4]\]. Disseminated disease at time of presentation is associated with 22% 5-year survival compared to 55% in patients without metastases \[[@rjy362C2]--[@rjy362C4]\]. However, the survival rate in patients without metastatic disease has improved to 86% \[[@rjy362C6], [@rjy362C10]\]. This increase in survival rate could be explained by the recent advances in the treatment \[[@rjy362C6], [@rjy362C10]\].

The treatment of choice in Ewings sarcoma is the multimodality treatment that includes surgery, radiotherapy and chemotherapy \[[@rjy362C2]\]. In our case, based on the histological diagnosis, immunohistochemistry and cytogenetics confirmation, the patient was treated with surgery followed by chemotherapy and radiotherapy. The patient remains symptom-free and maintains a very good quality of life after 2 years follow-up.

CONCLUSION {#rjy362s4}
==========

Ewing's sarcoma originating from the sinonasal tract is very rare. Although the diagnosis of the disease is challenging, it is feasible using histopathological examination, immunohistochemical study and cytogenetic analysis. Treatment includes a multidisciplinary approach with surgery followed by chemotherapy and radiotherapy.
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